McN 5707

Mcn 5707
Clinical data
Other namesMcN-5707
Identifiers
  • (6R,10bR)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H18ClN
Molar mass283.80 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2C3=CC=CC=C3[C@@H](CN2C1)C4=CC=CC=C4Cl
  • InChI=1S/C18H18ClN/c19-17-9-4-3-7-14(17)16-12-20-11-5-10-18(20)15-8-2-1-6-13(15)16/h1-4,6-9,16,18H,5,10-12H2/t16-,18-/m1/s1
  • Key:KWMNBUDYCCTHHL-SJLPKXTDSA-N

Mcn 5707 is a SNDRI agent designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.[1][2]

For related agents, see JNJ-7925476, McN 4612-z, McN-5292, McN-5558 & McN5652.

References

  1. ^ Maryanoff BE, Shank RP, Gardocki JF (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
  2. ^ Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, et al. (August 1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin". Journal of Medicinal Chemistry. 27 (8): 943–6. doi:10.1021/jm00374a001. PMID 6747993.